Genmab
Genmab A/S, a leading biotechnology company headquartered in Denmark (DK), is renowned for its innovative approach to developing differentiated antibody therapeutics. Founded in 1999, Genmab has made significant strides in the biopharmaceutical industry, focusing primarily on oncology and immunology. With a robust pipeline of proprietary and partnered products, Genmab's core offerings include monoclonal antibodies that target various cancers, distinguished by their unique mechanisms of action. The company has achieved notable milestones, including the successful development of its flagship product, Darzalex, which has transformed treatment paradigms for multiple myeloma. Positioned as a key player in the global biotechnology landscape, Genmab continues to expand its influence through strategic collaborations and a commitment to scientific excellence, solidifying its reputation as a pioneer in the field.
DitchCarbon Score
How does Genmab's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Genmab's score of 48 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Genmab's reported carbon emissions
In 2024, Genmab reported total carbon emissions of approximately 189,673,000 kg CO2e. This figure includes 534,000 kg CO2e from Scope 1 emissions, 1,163,000 kg CO2e from market-based Scope 2 emissions, and a significant 187,976,000 kg CO2e from Scope 3 emissions. The latter category encompasses various activities, with purchased goods and services contributing about 164,449,000 kg CO2e, followed by business travel at approximately 10,559,000 kg CO2e. In 2023, Genmab's total emissions were about 151,463,000 kg CO2e, with Scope 1 emissions at 317,000 kg CO2e, market-based Scope 2 emissions at 238,000 kg CO2e, and Scope 3 emissions reaching approximately 150,908,000 kg CO2e. The trend indicates a substantial reliance on Scope 3 emissions, which represent the majority of their carbon footprint. Despite these figures, Genmab has not publicly committed to specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or SBTi commitments. The company does not appear to inherit emissions data from any parent organisation, maintaining its own reporting standards. Overall, Genmab's emissions profile highlights the importance of addressing Scope 3 emissions, which are critical for achieving meaningful reductions in their overall carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 341,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 298,000 | 000,000 | 000,000 | 0,000,000 |
| Scope 3 | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Genmab is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
